STOCK TITAN

[6-K] AKANDA CORP. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Analyzing...
Positive
  • None.
Negative
  • None.

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2025

 

Commission File Number:  001-41324

 

AKANDA CORP.

(Name of registrant)

 

c/o Gowling WLG

100 King St. W, Suite 1600

Toronto, ON M5X 1G5

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

   Form 20-F             Form 40-F

 

 

 

 

 

Exhibit No.   Description
99.1   Press Release – Akanda Announces $12.0 Million Convertible Note Offering

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AKANDA CORP.
  (Registrant)
     
Date: September 12, 2025 By: /s/ Katie Field
    Name:  Katie Field
    Title: Interim Chief Executive Officer and Director

 

 

2

 

AKANDA CORP

NASDAQ:AKAN

AKAN Rankings

AKAN Latest News

AKAN Latest SEC Filings

AKAN Stock Data

2.76M
722.15k
0.8%
1.31%
3.76%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Toronto